Login to Your Account



Other News To Note


Monday, April 2, 2012
• Hunter Immunology Ltd., of Sydney, Australia, said it completed its merger with ASX-listed company Probiomics Ltd., of Gordon, Australia. The merged entity, which will be renamed Bioxyne and will focus on a midstage chronic obstructive pulmonary disease candidate, is due to relist on the Australian exchange on April 4.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription